Results 71 to 80 of about 11,074 (164)

Iron‐Photocatalyzed Ligand‐to‐Metal Charge Transfer‐Driven Decarboxylative Giese‐Type Reactions Under Mild Conditions

European Journal of Organic Chemistry, Volume 29, Issue 34, 11 September 2026.
Iron‐photocatalyzed LMCT enables decarboxylative hydroalkylation of Michael acceptors (Giese‐type reaction) under mild conditions. Using tailored ligands and a sterically hindered very mild aniline base, diverse carboxylic acids efficiently couple with sensitive Michael acceptors, including maleimides.
Luca Mareen Denkler, Amrita Chaudhuri, Tak Shing Jason Ngan, Ali Dbouk, Qing Zhuo, Onisha Herath Pathirannehalage, Christopher Heinz Köhler, Shen Yen Ho, Idris Karakaya, Ala Bunescu   +9 more
wiley   +1 more source

Process for the preparation of alectinib

, 2018
The present invention relates to a process for preparing alectinib or a pharmaceutically acceptable salt thereof. The present invention also relates to 5 intermediate compounds which are useful in such process and to the preparation of such intermediate ...
Walter Cabri, Alessandra Tolomelli, Lucia Ferrazzano, Assunta De Nisi   +3 more
core   +1 more source

Effects of crizotinib or alectinib on SPI.

, 2015
Effects of crizotinib or alectinib on SPI.
Makoto Kaneda (168546), Toshiyuki Ishii (53332), Shunichiro Iwasawa (782964), Yuichi Takiguchi (395734), Akemi Maeda (782966), Ryota Kurimoto (782965)   +5 more
core   +1 more source

Primary Pulmonary Epithelioid Inflammatory Myofibroblastic Sarcoma With SQSTM1::ALK Fusion

Diagnostic Cytopathology, Volume 54, Issue 9, Page E216-E220, September 2026.
ABSTRACT Epithelioid inflammatory myofibroblastic sarcoma (EIMS) is a rare and aggressive variant of inflammatory myofibroblastic tumor (IMT) characterized by epithelioid morphology, atypical features, ALK rearrangements, and early metastatic potential.
Havva Gokce Terzioglu, Phillip McMullen, Güliz A. Barkan   +2 more
wiley   +1 more source

Volumetric Microsampling for Patient‐Centric Therapeutic Drug Monitoring in Clinical Pharmacology: A Scoping Review

The Journal of Clinical Pharmacology, Volume 66, Issue 9, September 2026.
Abstract Accurate drug concentration measurement is essential for precision pharmacotherapy, but conventional therapeutic drug monitoring (TDM) requires venous sampling, increasing patient burden, and potentially limiting participation in TDM and model‐informed precision dosing (MIPD).
Hari Prabhath Tummala, Abbie D. Leino, Nathaniel J. Rhodes, Kevin J. Downes, Marc H. Scheetz, Manjunath P. Pai   +5 more
wiley   +1 more source

The efficacy and safety of ALK inhibitors in the treatment of ALK‐positive non‐small cell lung cancer: A network meta‐analysis

Cancer Medicine, 2018
Purpose The current study was carried out to compare the effectiveness and safety of different ALK inhibitors in treating ALK+ NSCLC. Methods Progression‐free survival (PFS), disease control rate (DCR), overall response rate (ORR), and intracranial ORR ...
Junsheng Fan, Tszhei Fong, Zengfei Xia, Jian Zhang, Peng Luo   +4 more
doaj   +1 more source

Alectinib as monotherapy for the firstline treatment of adult patients with ALKpositive advanced non-small cell lung cancer

, 2018
En este informe de la European Network for Health Technology Assessment (EUnetHTA), se evalúa la eficacia y seguridad relativas de alectinib, en comparación con crizotinib y ceritinib, en el tratamiento de primera línea en pacientes adultos con cáncer de

core  

Early Local Treatment Delays Multiple Metastases in Non‐Small Cell Lung Cancer With Solitary Distant Metastasis: A Multicenter Retrospective Cohort Study

MedComm, Volume 7, Issue 9, September 2026.
In NSCLC patients with solitary distant metastasis (SDM), early local treatment significantly delays the progression to multi‐metastasis by 14 months (HR = 0.55) compared to delayed or no treatment. This multicenter cohort study highlights SDM as an indolent state, emphasizing the critical time window for effective local intervention. .
Kang Miao, Siyu Lei, Xiaobin Zheng, Shanshan Yang, Yujing Li, Sihui Chen, Qian Miao, Longfeng Zhang, Zihua Zou, Haipeng Xu, Gen Lin   +10 more
wiley   +1 more source

Exposure-response analyses of anaplastic lymphoma kinase inhibitors crizotinib and alectinib in non-small cell lung cancer patients [PDF]

, 2020
Crizotinib and alectinib are anaplastic lymphoma kinase (ALK)-inhibitors indicated for the treatment of ALK-positive metastatic non-small cell lung cancer (NSCLC). At the currently used fixed doses, interindividual variability in exposure is high.
Geel, D.R., Smit, E.F., Huitema, A.D.R., Steeghs, N., Janssen, J.M., Groenland, S.L., Rosing, H., Burgers, J.A., Vries, N. de, Beijnen, J.H.   +9 more
core   +1 more source

Early‐Phase Research in Pediatric Neuro‐Oncology

Pediatric Blood &Cancer, Volume 73, Issue 10, October 2026.
Jonathan Cunningham
wiley   +1 more source